Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of GM-CSF in the treatment of acute myeloid leukemia.
Büchner T, Hiddemann W, Wörmann B, Rottmann R, Maschmeyer G, Ludwig WD, Zühlsdorf M, Buntkirchen K, Sander A, Aswald J, et al. Büchner T, et al. Among authors: ludwig wd. Leuk Lymphoma. 1993;11 Suppl 2:21-4. doi: 10.3109/10428199309064257. Leuk Lymphoma. 1993. PMID: 8124228 Clinical Trial.
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: ludwig wd. Leuk Lymphoma. 1993;10 Suppl:133-7. doi: 10.3109/10428199309149125. Leuk Lymphoma. 1993. PMID: 8481662 Clinical Trial.
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: ludwig wd. Leukemia. 1998 Jul;12(7):1049-55. doi: 10.1038/sj.leu.2401066. Leukemia. 1998. PMID: 9665189 Clinical Trial.
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. Büchner T, et al. Among authors: ludwig wd. Blood. 1999 Jun 15;93(12):4116-24. Blood. 1999. PMID: 10361108 Free article. Clinical Trial.
GM-CSF in the treatment of acute myeloid leukemia.
Hiddemann W, Maschmeyer G, Ludwig WD, Königsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, Agion-Freire E, Innig G, Reuter C, et al. Hiddemann W, et al. Among authors: ludwig wd. Pathol Biol (Paris). 1992 Nov;39(9):959. Pathol Biol (Paris). 1992. PMID: 1538952 No abstract available.
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
Büchner T, Hiddemann W, Wörmann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Grüneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, Griesinger F, Reichle A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: ludwig wd. Int J Hematol. 2000 Oct;72(3):285-9. Int J Hematol. 2000. PMID: 11185983
393 results